Clinical trial

Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable…

NCT00107549 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed

Key facts

NCT number NCT00107549
Title Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy
Official title A Phase I, Open-Label Study to Evaluate the Safety and Tolerability of Recombinant HIV-1 Vaccines in HIV-1 Infected Young Adults With Control of HIV-1 Replication and on Stable Highly Active Antiretroviral Therapy (HAART)
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID), NIH
Collaborators Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) NIH
Status Completed
Phase Phase 1
Study type Interventional
Conditions HIV Infections
Intervention type Biological
Interventions rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]), rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])
Enrollment 20
Completion Feb 1, 2009
First posted Apr 6, 2005
Last update posted Nov 1, 2021
Countries Puerto Rico, United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies